CJC-1295 vs Ipamorelin
GHRH Analog · Growth Hormone Secretagogue
Here is how these two compounds compare, based on published research, not marketing claims.
CJC-1295
A GHRH analog that sustains GH release for days; the GHRH-receptor side of the most common GH peptide pairing.
Ipamorelin
The most selective GH secretagogue; the ghrelin-receptor side of the most common GH peptide pairing.
CJC-1295
27 studies
2 human trials
Not FDA-Approved
Ipamorelin
48 studies
3 human trials
Not FDA-Approved
What it does
CJC-1295
Stretches a growth hormone signal that normally lasts minutes into one that lasts days. A small chemistry change attaches the molecule to albumin, a protein already circulating in the blood, which protects it from being broken down. In the published research, that translates to a half-life of roughly six to eight days, compared with minutes for the body's native GHRH.
Ipamorelin
Releases growth hormone without the cortisol or prolactin spike that older ghrelin agonists produced. The most receptor-selective compound in the GH secretagogue class for GHS-R1a, the ghrelin receptor itself. Comparable growth hormone elevation to GHRP-2 or GHRP-6 in head-to-head studies, without the hormonal collateral that made those compounds harder to study.
How it works
CJC-1295
A modified version of the body's natural growth hormone signal. The modification makes it resist breakdown, so it stays active longer in the bloodstream.
Ipamorelin
Ipamorelin acts on a single receptor on the pituitary gland (the ghrelin receptor, GHS-R1a) and triggers growth hormone release without touching the cortisol axis, the prolactin axis, or the appetite signal that older compounds in this class also activated. Other GH secretagogues like GHRP-6 and hexarelin raise cortisol alongside GH, raise prolactin, and sharpen hunger. Ipamorelin does not.
How often
CJC-1295
In Phase I/II trials, CJC-1295 with DAC was given as a subcutaneous injection once or twice per week. The DAC modification (drug affinity complex) extends the active window to several days, which is what allows the once-or-twice-weekly schedule rather than daily injection.
Ipamorelin
In published human pharmacokinetic studies (Johansen 1999), ipamorelin was given as a subcutaneous injection with dose-dependent GH response measured over hours. The Beck 2014 Phase II post-surgical trial used repeated dosing over days. Clinical protocols typically use daily subcutaneous injection, though this frequency derives from clinical practice rather than from controlled dose-optimization trials.
How strong
CJC-1295
Stronger and more sustained. A bigger growth hormone pulse that lasts longer.
Ipamorelin
Moderate GH elevation with the cleanest hormonal profile in the secretagogue class. The GH pulse follows the body's natural pulsatile pattern rather than producing sustained elevation. The selectivity advantage is the pharmacological identity of the molecule.
Main tradeoff
CJC-1295
Less pulsatile than the body's natural rhythm. Side effects, if they happen, stick around longer because the drug stays active longer.
Ipamorelin
The selectivity that makes ipamorelin distinctive is well documented, but clinical outcome data beyond the single Phase II post-surgical GI trial (Beck 2014) is absent. One of the most widely used peptides in clinical practice has almost no published outcomes data for the endpoints practitioners actually prescribe it for. The CJC-1295 plus ipamorelin combination has never been tested in a controlled comparison study despite being the most common clinical protocol.
Best for
CJC-1295
- People who want fewer injections per week
- People who've plateaued on Sermorelin
- Anyone planning to stack with Ipamorelin (a popular combination because the two work through different receptors and amplify each other)
Ipamorelin
- Research interest in selective GH secretagogues with minimal off-target hormonal effects
- Research comparing GH secretagogue selectivity profiles across the class
- Research contexts where the CJC-1295 plus ipamorelin pairing is the protocol under study
How to choose
A good fit for CJC-1295
- Research on GHRH receptor-mediated GH release with extended pharmacokinetics
- Research prioritizing fewer injections per week (once or twice weekly vs daily)
- Research on sustained GH elevation versus pulsatile release
A good fit for Ipamorelin
- Research on selective ghrelin-receptor GH release with zero off-target hormonal effects
- Research comparing GH secretagogue selectivity profiles across the class
- Research on pulsatile GH release that more closely mirrors the body's natural rhythm
Consider both across time
CJC-1295 and ipamorelin are most commonly discussed together because clinical protocols frequently combine them. The logic: CJC-1295 activates the GHRH receptor for sustained baseline GH elevation, while ipamorelin activates the ghrelin receptor for clean pulsatile GH release on top of that baseline. The dual-receptor approach is intended to produce a larger combined response than either compound alone. No controlled study of the combination has been published; the pairing is based on mechanistic reasoning and clinical practice. For the stack comparison against the oral alternative, see CJC-1295/Ipamorelin Stack vs MK-677.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GHRH Receptor
- GHRH Receptor activates GHRH Signaling
- GHRH Signaling connects to Anterior Pituitary; Ghrelin Mimicry connects to Anterior Pituitary
- Anterior Pituitary connects to Growth Hormone Release
- Growth Hormone Release connects to IGF-1 Elevation
- GHS-R1a Receptor
- GHS-R1a Receptor activates Ghrelin Mimicry
CJC-1295 mimics GHRH to tell the pituitary gland to release growth hormone; the DAC modification extends activity from minutes to days.
Ipamorelin selectively binds the ghrelin receptor on pituitary somatotrophs to trigger growth hormone release without raising cortisol or prolactin.
Research Evidence
CJC-1295 has Phase I/II pharmacokinetic data characterizing sustained GH release from the DAC modification. Ipamorelin has 48 published studies with human pharmacodynamic data confirming the selectivity profile (Raun 1998, Johansen 1999) and a Phase II post-surgical GI recovery trial (Beck 2014). Despite being the most commonly prescribed GH peptide combination, the CJC-1295 plus ipamorelin pairing has never been studied in a controlled comparison trial. The evidence base for each compound individually is stronger than the evidence for the combination.
- 1.
If the research interest is sustained GH elevation for body composition or anti-aging research, CJC-1295 (especially the DAC variant) provides the most relevant pharmacokinetic data.
- 2.
If the research interest is selective GH stimulation without cortisol or prolactin effects, ipamorelin's selectivity profile is uniquely documented among GHS peptides.
- 3.
If the research interest is GI recovery or post-operative applications, ipamorelin has the most directly relevant (though limited) human data.
- 4.
If the research question involves combination GH stimulation protocols, the CJC-1295/ipamorelin pairing has mechanistic rationale but limited formal study.
Key Limitations
- •Neither compound has completed Phase III clinical trials for any therapeutic endpoint.
- •The CJC-1295 + ipamorelin combination is widely discussed but has minimal formal research support.
- •CJC-1295's DAC variant produces non-physiological sustained GH elevation, the long-term implications are unknown.
- •Ipamorelin's selectivity advantage is established in animal models but not confirmed as clinically meaningful in humans.
- •Both compounds exist in a regulatory gray area and are not approved for human therapeutic use.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
CJC-1295
"CJC-1295 with DAC gives you sustained growth hormone elevation for days"
Supported by published data
"Stacking CJC-1295 with ipamorelin is the gold standard for GH optimization"
Plausible but unproven
"It made me retain water and feel bloated"
Supported by published data
Ipamorelin
"Ipamorelin is the cleanest GH secretagogue with the fewest side effects"
Plausible but unproven
"Combined with CJC-1295 it mimics natural GH pulsing"
Plausible but unproven
"It helped with my joint pain and recovery"
Anecdotal only
Safety Comparison
Both compounds have favorable safety profiles. CJC-1295 side effects include injection site reactions, water retention, and numbness. Ipamorelin's published pharmacodynamic data specifically documents the absence of cortisol, prolactin, and ACTH changes at GH-stimulating doses. Neither compound's long-term safety has been characterized in controlled trials. Compounded versions are not FDA-regulated.
CJC-1295
Phase II data (Teichman et al., 2006) showed CJC-1295 with DAC was generally well-tolerated. Most common side effects: injection site reactions, flushing, and headache. The sustained GH elevation from DAC variant raises theoretical concerns about prolonged IGF-1 exposure, though this has not been confirmed as clinically significant.
Ipamorelin
Animal studies demonstrate favorable selectivity: GH release without cortisol or prolactin elevation. Limited human safety data. One Phase II trial in post-operative patients showed tolerability but was not designed as a safety study.
What the Research Suggests
Both compounds sit at PSI Animal Studies: each has some human pharmacology data, but neither has a broad Phase III-style program or outcome trials. CJC-1295 is better characterized for sustained GH/IGF-1 pharmacokinetics (especially with DAC). Ipamorelin's standout feature is documented selectivity among GH secretagogues. The widely discussed combination has mechanistic rationale but minimal formal study. The meaningful comparison is mechanism and side-effect profile, not a large gap in evidence tier.